News & Updates

Among patients receiving hydroxychloroquine for systemic lupus erythematosus (SLE), severe nonadherence to medication poses increased risks of SLE flare in the following year, early damage, and 5-year mortality, according to data from the SLICC* Inception Cohort.

For older adults with chronic kidney disease (CKD) who are initiating a disease-modifying antirheumatic drug (DMARD), low-dose methotrexate appears to be associated with a heightened 90-day risk of serious adverse events compared with hydroxychloroquine, as shown in a study.

Axial spondyloarthritis (axSpA) patients with a higher inflammatory burden, longer delay in diagnosis and longer baseline disease duration (BLDD) have an increased risk of developing incident hypertension after adjusting for traditional cardiovascular (CV) risk factors, a retrospective cohort study by the Chinese University of Hong Kong has shown.  

Avacopan, when added to background induction therapy with rituximab, is as efficacious as a prednisone taper in terms of inducing remission at week 26 and is associated with a higher rate of sustained remission at week 52 in patients with antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, according to the phase III ADVOCATE trial.

The selective potent oral BTK inhibitor remibrutinib has shown favourable efficacy and safety in the treatment of patients with Sjögren’s syndrome, according to the results of a phase II trial.

Patients with axial spondyloarthritis (axSpA) who are in a low disease activity (LDA) state or in remission tend to experience residual disease, which occurs more frequently among female patients, reveals a recent study.

Exposure to Janus kinase (JAK) inhibitors potentially carries an increased likelihood of developing acne, according to a study.

New drug applications approved by US FDA as of 16-31 October 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.